✦ LIBER ✦

Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: A 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis

✍ Scribed by Mayosi, Bongani M.; Ntsekhe, Mpiko; Bosch, Jackie; Pogue, Janice; Gumedze, Freedom; Badri, Motasim; Jung, Hyejung; Pandie, Shaheen; Smieja, Marek; Thabane, Lehana; Francis, Veronica; Thomas, Kandithal M.; Thomas, Baby; Awotedu, Abolade A.; Magula, Nombulelo P.; Naidoo, Datshana P.; Damasceno, Albertino; Banda, Alfred Chitsa; Mutyaba, Arthur; Brown, Basil; Ntuli, Patrick; Mntla, Phindile; Ntyintyane, Lucas; Ramjee, Rohan; Manga, Pravin; Kirenga, Bruce; Mondo, Charles; Russell, James B.W.; Tsitsi, Jacob M.; Peters, Ferande; Essop, Mohammed R.; Barasa, Ayub Felix; Mijinyawa, Muhammad S.; Sani, Mahmoud U.; Olunuga, Taiwo; Ogah, Okechukwu; Adebiyi, Adewole; Aje, Akinyemi; Ansa, Victor; Ojji, Dike; Danbauchi, Solomon; Hakim, James; Matenga, Jonathan; Yusuf, Salim

Book ID: 121419312
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 684 KB
Volume: 165
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2012.08.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and design of the INFUSE-AMI s

Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction

✍ C. Michael Gibson; Akiko Maehara; Alexandra J. Lansky; Jochen Wohrle; Tom Stucke 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 826 KB

A multicenter, randomized, placebo-contr

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

✍ E. J. Rhee; W. Y. Lee; K. H. Yoon; S. J. Yoo; I. K. Lee; S. H. Baik; Y. K. Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB

Randomized Double-Blind, Placebo-Control

Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck

✍ Mix, M.D.; Jameson, M.; Tills, M.; Dibaj, S.; Groman, A.; Jaggernauth, W.; Rustu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 76 KB

A multicentre, randomized, double-blind

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial

✍ Olivier F. Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 803 KB

Design and rationale of the Treatment of

Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy

✍ Philippe Gabriel Steg; Shamir R. Mehta; Charles V. Pollack Jr.; Christoph Bode; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 398 KB

Rationale and design of the randomized,

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

✍ Sergio Leonardi; Sunil V. Rao; Robert A. Harrington; Deepak L. Bhatt; C. Michael 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 375 KB